News

MedCity News3d
BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...
FDA approves expanded use of Moderna’s RSV shot, but uncertainty remains
The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include people 18 to ...
STAT5d
‘People inside Moderna are afraid’: As anti-vaccine climate intensifies, the company has much to lose
The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...
Shining a Light on the World of Tiny Proteins
For a long time, scientists depended on luck to find new proteins. In 1840, for example, Friedrich Ludwig Hünefeld, a German ...
Metro Weekly2d
HIV Cure Could Emerge From COVID-19 mRNA Breakthrough
Researchers in Australia use COVID-era mRNA technology to expose hidden HIV in white blood cells, offering hope for a future ...
Chemistry World4d
RNA as a replacement for chemical pesticides
Replacing some chemical pesticides with potentially safer, more environmentally benign alternatives is a significant ...
US FDA approves expanded use of Moderna's RSV vaccine for at-risk adults
The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...
Why Trump turned against ‘gold standard’ mRNA vaccines
President Trump’s administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their lifesaving potential during the COVID-19 pandemic but have come ...
BioNTech's Acquisition Of CureVac Brings Complementary Method To Target Cancer
The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...